DMAANasdaqBlank ChecksFiscal year ends December 31Also trades as DMAAR, DMAAU
Drugs Made In America Acquisition Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$10.87+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
14M
Shares held, 13F filers
Institutional holders
23
1 new, 17 sold out
Net institutional buying
-9M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Drugs Made In America Acquisition LLC | 4,188,780 | 12.50% | 13D (active) | Feb 18, 2025 |
| Karpus Management, Inc. | 2,507,817 | 10.33% | 13G (passive) amendment | Jun 30, 2026 |
| Mizuho Financial Group, Inc. | 2,058,605 | 8.50% | 13G (passive) amendment | Jun 30, 2026 |
| Polar Asset Management Partners Inc. | 1,900,000 | 5.70% | 13G (passive) | Mar 31, 2025 |
| Glazer Capital, LLC | 1,822,952 | 5.44% | 13G (passive) | Mar 31, 2025 |
| Feis Equities LLC | 1,232,775 | 5.08% | 13G (passive) | Jun 18, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DMAA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Mizuho Securities USA LLC | 4,069,605 | – | $42.83M | +2,069,605 | 0.41% |
| Karpus Management, Inc. | 2,507,817 | – | $26.71M | −22,700 | 0.77% |
| Polar Asset Management Partners Inc. | 1,146,000 | – | $12.20M | −454,000 | 0.20% |
| Glazer Capital, LLC | 999,899 | – | $10.65K | −678,507 | 0.26% |
| Wolverine Asset Management LLC | 832,093 | – | $8.86M | −721,615 | 0.08% |
| Highbridge Capital Management LLC | 809,054 | – | $8.62M | −514,297 | 0.21% |
| First Trust Capital Management L.P. | 786,459 | – | $8.38M | −1,456,041 | 0.49% |
| Heights Capital Management, Inc | 648,083 | – | $6.90M | −1,917 | 1.59% |
| Westchester Capital Management, LLC | 581,790 | – | $6.20M | −1,087,210 | 0.30% |
| Clear Street Group Inc. | 382,440 | – | $1.65M | +28,392 | 0.00% |
| Aristeia Capital LLC | 350,000 | – | $3.73M | −531,716 | 0.05% |
| Sona Asset Management (US) LLC | 162,795 | – | $1.73M | – | 0.04% |
| RLH Capital LLC | 115,606 | – | $1.23M | −200,945 | 0.59% |
| Logan Stone Capital, LLC | 109,959 | – | $1.17M | New | 0.25% |
| Toronto Dominion Bank | 100,000 | – | $1.07M | −103,838 | 0.00% |
| Meteora Capital, LLC | 97,837 | – | $1.04M | −282,462 | 0.09% |
| Quarry LP | 65,551 | – | $698.12K | −201,000 | 0.06% |
| Geode Capital Management, LLC | 62,273 | – | $663.21K | – | 0.00% |
| JPMorgan Chase & Co | 49,891 | – | $531.34K | +10 | 0.00% |
| Dakota Wealth Management | 36,400 | – | $387.66K | – | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 23 | 14M | 1 / 3 | 15 / 17 | 2M | 11M |
| Q1 2026 | 39 | 23M | 6 / 7 | 7 / 6 | 3M | 3M |
| Q4 2025 | 39 | 23M | 4 / 11 | 7 / 1 | 2M | 1M |
| Q3 2025 | 37 | 22M | 11 / 6 | 9 / 5 | 3M | 1M |
| Q2 2025 | 32 | 21M | 11 / 7 | 6 / 2 | 5M | 3M |
| Q1 2025 | 24 | 20M | 24 / 0 | 0 / 0 | 20M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of DMAA | Value | % of fund | As of |
|---|---|---|---|---|---|
| First Trust Merger Arbitrage Fund | 675,366 | – | $7.19M | 0.44% | Jun 30, 2026 |
| First Trust Multi-Strategy Fund | 105,083 | – | $1.12M | 0.08% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Lynn Stockwell | CEO and Exe. Chair of Board, Director, 10% owner | 4,188,780 | Feb 18, 2025 |
| Glenn C. Worman | CFO | 100,000 | Feb 3, 2025 |
| Catherine Do | Director | 100,000 | Feb 3, 2025 |
| Myron W. Shulgan | Director | 100,000 | Feb 3, 2025 |
| Sridhar G. Prasad | Director | 100,000 | Feb 3, 2025 |
| Made In America Acquisition LLC Drugs | 10% owner | 4,188,780 | Feb 18, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Lynn Stockwell CEO and Exe. Chair of Board, Director, 10% owner | Feb 18, 2025 | Buy | +30,000 | – | – | 4,188,780 |
| Made In America Acquisition LLC Drugs 10% owner | Feb 18, 2025 | Buy | +30,000 | – | – | 4,188,780 |
| Lynn Stockwell CEO and Executive COB, Director, 10% owner | Jan 29, 2025 | Buy | +400,000 | – | – | 10,257 |
| Lynn Stockwell CEO and Executive COB, Director, 10% owner | Jan 29, 2025 | Other | −400,000 | – | – | 9,857,143 |
| Lynn Stockwell CEO and Executive COB, Director, 10% owner | Jan 29, 2025 | Sale | −5,698,363 | – | – | 4,158,780 |
| Made In America Acquisition LLC Drugs 10% owner | Jan 29, 2025 | Other | −400,000 | – | – | 9,857,143 |
| Made In America Acquisition LLC Drugs 10% owner | Jan 29, 2025 | Sale | −5,698,363 | – | – | 4,158,780 |
| Made In America Acquisition LLC Drugs 10% owner | Jan 29, 2025 | Buy | +400,000 | – | – | 10,257,143 |
| Sridhar G. Prasad Director | Jan 29, 2025 | Other | +100,000 | – | – | 100,000 |
| Myron W. Shulgan Director | Jan 29, 2025 | Other | +100,000 | – | – | 100,000 |
| Catherine Do Director | Jan 29, 2025 | Other | +100,000 | – | – | 100,000 |
| Glenn C. Worman CFO | Jan 29, 2025 | Other | +100,000 | – | – | 100,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.